Skip to main content

Table 2 Characteristics of Included Studies

From: Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials

Study Co-interventions Transfusion threshold Anti-platelet use
Isetta et al. [25] PO CS - re-transfusion of SMB Hct<20% during CPB
Hct<25% 4 hrs post CPB
Hct<27% post-op.
NR
Blauhut et al. [27] NR Hct<30% post-op. Excluded pts. pre-operatively treated with ASA + NSAIDs
Penta de Peppo et al. [20] IO CS + IO & PO re-transfusion of SMB Post-op. non-monitored pts. Hb<7.0 g/dL
Monitored pts. Hb<8.5 g/dL
Discontinued NSAIDs 24 hrs before Sx.
Corbeau et al. [23] NR Hct<20% during CPB
Hct<25% at the end of surgery
Hct<30 post extubation
Anti-platelet aggregation drugs ceased 10 days pre-operatively
Pugh et al. [22] IO CS + ANH (1 unit of WB collected pre-CPB then re-transfused post CPB) Hct<20% during CPB
Hct<30% off CPB
Aspirin use within 10 days of the operation: LD APR = 67%, TXA = 91%, Control = 78%
Speekenbrink et al. [21] NR NR Aspirin discontinued 2–4 days before Sx.
Menichetti et al. [24] NR Hct<30% post-operatively Excluded pts. who had taken ASA or DIP until 2 weeks pre-op.
Pinosky et al. [33] NR Hct<20% + surgeon preference Pre-operative aspirin use: TXA = 25%, EACA = 40%, Placebo = 42%
Mongan et al. [31] NR Hb<6.0 g/dL during CPB
Hb<8.0 g/dL off CPB
Pre-operative aspirin use: HD APR = 44%, TXA = 53%
Hardy et al. [26] IO CS & Re-infusion of SMB were not used Hb<7.0 g/dL during CPB
Hb<8.0 g/dL off CPB
NR
Eberle et al. [29] IO & PO CS used Hct<27% - post-operative + accompanied by signs & symptoms of hypovolemia Intra-operative IV ASA: HD APR = 5.0%, EACA = 15%
Misfeld et al. [30] NR Hb<8.0 g/dL Excluded pts. receiving ASA treatment within 5 days of Sx.
Casati et al. [28] IO CS used + PAD Hb<6.0 g/dL during CPB
Hb<8.0 g/dL off CPB + clinical condition
Pts. receiving ASA treatment within 5 days of Sx.: HD APR = 37.8%, TXA = 40.9%, EACA = 35.3%
Bernet et al. [34] PO CS Hct<25% PO All pts. were treated with 100 mg ASA daily until Sx.
Nuttall et al. [32] PAD not used Hb<7.0 g/dL during CPB Excluded pts. taking ASA daily (≥325 mg) before Sx.
Maineri et al. [38] IO CS + PO re-infusion of SMB Hct<30% IO
Hct<28% PO
NR
Wong et al. [37] IO CS + PO re-infusion of SMB Hb<7.0 g/dL IO
Hb<8.0 g/dL PO
Excluded pts. receiving ASA treatment within 5 days of Sx.
Casati et al. [35] IO CS used Hb<6.0 g/dL during CPB
Hb<8.0 g/dL PO
Pts. receiving ASA treatment before Sx.: HD APR = 17.8%, TXA = 18.8%
Greilich et al. [36] IO CS used PO SMB was not used Hb<8.0 g/dL Pts. receiving ASA treatment before Sx.: HD APR = 88%, EACA = 90%, Placebo = 79%
Ray et al. [6] NR NR ASA within 10 days before Sx.: LD APR = 22.4%, EACA = 33.3%
  1. ANH = acute normovolemic hemodilution, APR = aprotinin, ASA = acetylsalicylic acid, CABG = coronary artery bypass graft, CPB = cardiopulmonary bypass, CS = cell salvage, DIP = dipyridamole, EACA = epsilon aminocaproic acid, Hb = hemoglobin, Hct = hematocrit, HD = high dose, LD = low dose, NR = not reported, NSAIDs = non-steroidal anti-inflammatory drugs, PP = pump prime, IO = intra-operative, PO = post-operative, SMB = shed mediastinal blood, Sx. = surgery, TXA = tranexamic acid, WB = whole blood